These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Fox RJ; Bethoux F; Goldman MD; Cohen JA Cleve Clin J Med; 2006 Jan; 73(1):91-102. PubMed ID: 16444920 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach? Chofflon M BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071 [TBL] [Abstract][Full Text] [Related]
10. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? Klawiter EC; Cross AH; Naismith RT Neurology; 2009 Sep; 73(12):984-90. PubMed ID: 19770475 [TBL] [Abstract][Full Text] [Related]
11. [Current treatment of multiple sclerosis]. Gout O; Bensa C; Assouad R Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785 [TBL] [Abstract][Full Text] [Related]
13. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related]
14. New and emerging treatment options for multiple sclerosis. Polman CH; Uitdehaag BM Lancet Neurol; 2003 Sep; 2(9):563-6. PubMed ID: 12941579 [TBL] [Abstract][Full Text] [Related]
15. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738 [TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967 [TBL] [Abstract][Full Text] [Related]
18. [Pharmacological treatment of multiple sclerosis]. Myhr KM Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616 [TBL] [Abstract][Full Text] [Related]